<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2072-0351-5551</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-5551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Координационный совет по ранней инсулинотерапии</article-title><trans-title-group xml:lang="en"><trans-title>Early insulin therapy Coordination Council</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестакова</surname><given-names>Марина Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Shestakova</surname><given-names>Marina Vladimirovna</given-names></name></name-alternatives><email xlink:type="simple">nephro@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ "Эндокринологический научный центр" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2012</year></pub-date><volume>15</volume><issue>4</issue><issue-title>№4 (2012)</issue-title><fpage>128</fpage><lpage>131</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шестакова М.В., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Шестакова М.В.</copyright-holder><copyright-holder xml:lang="en">Shestakova M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/5551">https://www.dia-endojournals.ru/jour/article/view/5551</self-uri><abstract><p>Координационный совет указал на важность ведения пациентов в соответствии с принципами, заложенными в российские и международные рекомендации по лечению сахарного диабета 2 типа (СД2), а также на важное место инсулинотерапии в лечении пациентов. Инсулинотерапия при СД2 сохраняет инсулинсекреторную функцию поджелудочной железы, является самым эффективным гипогликемическим средством, предотвращает или задерживает развитие микрососудистых осложнений.</p></abstract><trans-abstract xml:lang="en"><p>Coordination Council has denoted the importance of adherence to Russian and international guidelines and prominent role of insulin therapy in management of type 2 diabetes mellitus (T2DM). Insulin therapy in T2DM preserves endogenous insulin secretion, prevents or decelerates development of microvascular complications and is known to be the most effective glucose-lowering treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>инсулинотерапия</kwd><kwd>гликемический контроль</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>insulin therapy</kwd><kwd>glycemic control</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">IDF Diabetes Atlas, 5th edition, 2011.</mixed-citation><mixed-citation xml:lang="en">IDF Diabetes Atlas, 5th edition, 2011.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dedov II, Shestakova MV. Sakharnyy diabet v pozhilom vozraste: diagnostika, klinika, lechenie. Prakticheskoe rukovodstvo dlya vrachey. Moscow. 2011.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV. Sakharnyy diabet v pozhilom vozraste: diagnostika, klinika, lechenie. Prakticheskoe rukovodstvo dlya vrachey. Moscow. 2011.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ametov AS. Sakharnyy diabet 2 tipa. Osnovy patogeneza i terapii. Moscow; 2003.</mixed-citation><mixed-citation xml:lang="en">Ametov AS. Sakharnyy diabet 2 tipa. Osnovy patogeneza i terapii. Moscow; 2003.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ametov AS. Insulinoterapiya. Sakharnyy diabet 2 tipa, problemy i resheniya. Moscow; 2011.</mixed-citation><mixed-citation xml:lang="en">Ametov AS. Insulinoterapiya. Sakharnyy diabet 2 tipa, problemy i resheniya. Moscow; 2011.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">UKPDS Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995 Nov;44(11):1249-1258.</mixed-citation><mixed-citation xml:lang="en">UKPDS Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995 Nov;44(11):1249-1258.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dedov II, Shestakova MV, Ametov AS, Antsiferov MB, Galstyan GR, Mayorov AYu, Mkrtumyan AM, Petunina NA, Sukhareva OYu. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapy in type 2 diabetes mellitus. Diabetes mellitus. 2011;(4):6-17.</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Ametov AS, Antsiferov MB, Galstyan GR, Mayorov AYu, Mkrtumyan AM, Petunina NA, Sukhareva OYu. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapy in type 2 diabetes mellitus. Diabetes mellitus. 2011;(4):6-17.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
